Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
3 recherche sur le mot-clé 'Electronic medical records'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Maternal metabolic risk factors for autism spectrum disorder—An analysis of electronic medical records and linked birth data / Natalia CONNOLLY in Autism Research, 9-8 (August 2016)
[article]
Titre : Maternal metabolic risk factors for autism spectrum disorder—An analysis of electronic medical records and linked birth data Type de document : Texte imprimé et/ou numérique Auteurs : Natalia CONNOLLY, Auteur ; Julia ANIXT, Auteur ; Patty MANNING, Auteur ; Daniel PING-I LIN, Auteur ; Keith A. MARSOLO, Auteur ; Katherine BOWERS, Auteur Article en page(s) : p.829-837 Langues : Anglais (eng) Mots-clés : autism obesity gestational diabetes mellitus epidemiology electronic medical records Index. décimale : PER Périodiques Résumé : Past studies have suggested that conditions experienced by women during pregnancy (e.g. obesity and gestational diabetes mellitus (GDM)) may be associated with having a child with autism spectrum disorder (ASD). Our objective was to compare mothers who had a child diagnosed with ASD to mothers of children with a non-ASD developmental disorder (DD) or without any reported DD (controls). To accomplish the objective we collected medical record data from patients who resided in the Cincinnati Children's Hospital Medical Center's (CCHMC) primary catchment area and linked those data to data from birth certificates (to identify risk factors). Two comparison groups were analyzed; one with DD; and the other, controls without a reported ASD or DD. Descriptive statistics and regression analyses evaluated differences. Differences were greater comparing mothers of ASD to controls than comparing ASD to DD. Maternal obesity and GDM were associated with a statistically significant approximately 1.5-fold increased odds of having a child with an ASD. For mothers with both GDM and obesity, the association was twofold for having a child with ASD compared with controls. Maternal obesity and GDM might be associated with an increased risk of ASD in the offspring; however, no difference in risk of ASD according to BMI and GDM was seen when comparing to DD. Autism Res 2016, 9: 829–837,. © 2016 En ligne : http://dx.doi.org/10.1002/aur.1586 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=293
in Autism Research > 9-8 (August 2016) . - p.829-837[article] Maternal metabolic risk factors for autism spectrum disorder—An analysis of electronic medical records and linked birth data [Texte imprimé et/ou numérique] / Natalia CONNOLLY, Auteur ; Julia ANIXT, Auteur ; Patty MANNING, Auteur ; Daniel PING-I LIN, Auteur ; Keith A. MARSOLO, Auteur ; Katherine BOWERS, Auteur . - p.829-837.
Langues : Anglais (eng)
in Autism Research > 9-8 (August 2016) . - p.829-837
Mots-clés : autism obesity gestational diabetes mellitus epidemiology electronic medical records Index. décimale : PER Périodiques Résumé : Past studies have suggested that conditions experienced by women during pregnancy (e.g. obesity and gestational diabetes mellitus (GDM)) may be associated with having a child with autism spectrum disorder (ASD). Our objective was to compare mothers who had a child diagnosed with ASD to mothers of children with a non-ASD developmental disorder (DD) or without any reported DD (controls). To accomplish the objective we collected medical record data from patients who resided in the Cincinnati Children's Hospital Medical Center's (CCHMC) primary catchment area and linked those data to data from birth certificates (to identify risk factors). Two comparison groups were analyzed; one with DD; and the other, controls without a reported ASD or DD. Descriptive statistics and regression analyses evaluated differences. Differences were greater comparing mothers of ASD to controls than comparing ASD to DD. Maternal obesity and GDM were associated with a statistically significant approximately 1.5-fold increased odds of having a child with an ASD. For mothers with both GDM and obesity, the association was twofold for having a child with ASD compared with controls. Maternal obesity and GDM might be associated with an increased risk of ASD in the offspring; however, no difference in risk of ASD according to BMI and GDM was seen when comparing to DD. Autism Res 2016, 9: 829–837,. © 2016 En ligne : http://dx.doi.org/10.1002/aur.1586 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=293 Psychiatric Comorbidities and Psychotropic Medication Use in Autism: A Matched Cohort Study with ADHD and General Population Comparator Groups in the United Kingdom / R. HOUGHTON in Autism Research, 11-12 (December 2018)
[article]
Titre : Psychiatric Comorbidities and Psychotropic Medication Use in Autism: A Matched Cohort Study with ADHD and General Population Comparator Groups in the United Kingdom Type de document : Texte imprimé et/ou numérique Auteurs : R. HOUGHTON, Auteur ; C. LIU, Auteur ; Federico BOLOGNANI, Auteur Article en page(s) : p.1690-1700 Langues : Anglais (eng) Mots-clés : United Kingdom attention deficit hyperactivity disorder autism spectrum disorder electronic medical records polypharmacy psychiatric comorbidities psychotropic medications Index. décimale : PER Périodiques Résumé : Psychiatric comorbidities and use of psychotropic medications are common among patients with autism spectrum disorder (ASD). However, most previous research used data from the United States (US) and few studies have compared medication use in ASD to control groups, making contextualization of results difficult. In the United Kingdom (UK), general practitioners play a key role in the management of ASD. We conducted a retrospective, cross-sectional study over calendar year 2015, using primary care data from the UK. We identified a prevalent cohort of ASD cases (n = 10,856) and matched control groups of (a) general population (n = 21,712) and (b) attention deficit hyperactivity disorder (ADHD; n = 7,058) on age, sex and region. We described psychiatric comorbidities, psychotropic medications, and healthcare utilization in all three cohorts. Within the ASD cohort, we used multivariable logistic regression models to explore associations between patient characteristics and the outcomes of: any psychotropic medication, polypharmacy, and number of primary care visits. We used conditional logistic regression to compare the ASD and control groups. Psychiatric comorbidities were recorded for 41.5% of ASD patients; 32.3% received psychotropic medication and 9.8% received polypharmacy. Increased age and all psychiatric comorbidities (except conduct disorder) were associated with treatment use. Males were less likely to receive a treatment than females [Odds ratio (OR) 0.74 (0.66-0.83)]. ASD patients were more likely to take psychotropic medications than the general population [OR 4.91 (4.46-5.40)], but less likely compared to ADHD patients [OR 0.40 (0.37-0.44)]. Overall, rates of medication use in the UK were lower than those previously reported in the US. Autism Research 2018, 11: 1690-1700. (c) 2018 International Society for Autism Research, Wiley Periodicals, Inc. LAY SUMMARY: We used electronic medical records from the UK, to describe the amount of psychiatric comorbidities, psychotropic medication use and healthcare resource use in ASD. Around one in three people with ASD were prescribed a psychotropic medication, which was more than the general population, but less than for those with ADHD. Increased age, psychiatric comorbidities and female gender were all independently associated with psychotropic medication use. Rates of medication use in the UK were lower than those previously reported in the US. En ligne : http://dx.doi.org/10.1002/aur.2040 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=372
in Autism Research > 11-12 (December 2018) . - p.1690-1700[article] Psychiatric Comorbidities and Psychotropic Medication Use in Autism: A Matched Cohort Study with ADHD and General Population Comparator Groups in the United Kingdom [Texte imprimé et/ou numérique] / R. HOUGHTON, Auteur ; C. LIU, Auteur ; Federico BOLOGNANI, Auteur . - p.1690-1700.
Langues : Anglais (eng)
in Autism Research > 11-12 (December 2018) . - p.1690-1700
Mots-clés : United Kingdom attention deficit hyperactivity disorder autism spectrum disorder electronic medical records polypharmacy psychiatric comorbidities psychotropic medications Index. décimale : PER Périodiques Résumé : Psychiatric comorbidities and use of psychotropic medications are common among patients with autism spectrum disorder (ASD). However, most previous research used data from the United States (US) and few studies have compared medication use in ASD to control groups, making contextualization of results difficult. In the United Kingdom (UK), general practitioners play a key role in the management of ASD. We conducted a retrospective, cross-sectional study over calendar year 2015, using primary care data from the UK. We identified a prevalent cohort of ASD cases (n = 10,856) and matched control groups of (a) general population (n = 21,712) and (b) attention deficit hyperactivity disorder (ADHD; n = 7,058) on age, sex and region. We described psychiatric comorbidities, psychotropic medications, and healthcare utilization in all three cohorts. Within the ASD cohort, we used multivariable logistic regression models to explore associations between patient characteristics and the outcomes of: any psychotropic medication, polypharmacy, and number of primary care visits. We used conditional logistic regression to compare the ASD and control groups. Psychiatric comorbidities were recorded for 41.5% of ASD patients; 32.3% received psychotropic medication and 9.8% received polypharmacy. Increased age and all psychiatric comorbidities (except conduct disorder) were associated with treatment use. Males were less likely to receive a treatment than females [Odds ratio (OR) 0.74 (0.66-0.83)]. ASD patients were more likely to take psychotropic medications than the general population [OR 4.91 (4.46-5.40)], but less likely compared to ADHD patients [OR 0.40 (0.37-0.44)]. Overall, rates of medication use in the UK were lower than those previously reported in the US. Autism Research 2018, 11: 1690-1700. (c) 2018 International Society for Autism Research, Wiley Periodicals, Inc. LAY SUMMARY: We used electronic medical records from the UK, to describe the amount of psychiatric comorbidities, psychotropic medication use and healthcare resource use in ASD. Around one in three people with ASD were prescribed a psychotropic medication, which was more than the general population, but less than for those with ADHD. Increased age, psychiatric comorbidities and female gender were all independently associated with psychotropic medication use. Rates of medication use in the UK were lower than those previously reported in the US. En ligne : http://dx.doi.org/10.1002/aur.2040 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=372 Validation of Autism Diagnosis and Clinical Data in the SPARK Cohort / Eric FOMBONNE in Journal of Autism and Developmental Disorders, 52-8 (August 2022)
[article]
Titre : Validation of Autism Diagnosis and Clinical Data in the SPARK Cohort Type de document : Texte imprimé et/ou numérique Auteurs : Eric FOMBONNE, Auteur ; Leigh COPPOLA, Auteur ; Sarah MASTEL, Auteur ; Brian J. O'ROAK, Auteur Article en page(s) : p.3383-3398 Langues : Anglais (eng) Mots-clés : Autism Spectrum Disorder/diagnosis Autistic Disorder/diagnosis Caregivers Child Cohort Studies Databases, Factual Female Humans Male Adults Autism Birth weight Electronic medical records Intellectual disability Language delay Parental report Regression SPARK cohort Sex differences Validity Index. décimale : PER Périodiques Résumé : The SPARK cohort was established to facilitate recruitment in studies of large numbers of participants with autism spectrum disorder (ASD). Online registration requires participants to have received a lifetime professional diagnosis by health or school providers although diagnoses are not independently verified. This study was set to examine the validity of self- and caregiver-reported autism diagnoses. Electronic medical records (EMR) of 254 SPARK participants (77.6% male, age 10.7Â years) were abstracted. Using two different methods, confirmation of ASD diagnosis in EMRs was obtained in 98.8% of cases. Core clinical features recorded in EMRs were typical of autism samples and showed very good agreement with SPARK cohort data, providing further evidence of the validity of clinical information in the SPARK database. En ligne : http://dx.doi.org/10.1007/s10803-021-05218-y Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=485
in Journal of Autism and Developmental Disorders > 52-8 (August 2022) . - p.3383-3398[article] Validation of Autism Diagnosis and Clinical Data in the SPARK Cohort [Texte imprimé et/ou numérique] / Eric FOMBONNE, Auteur ; Leigh COPPOLA, Auteur ; Sarah MASTEL, Auteur ; Brian J. O'ROAK, Auteur . - p.3383-3398.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 52-8 (August 2022) . - p.3383-3398
Mots-clés : Autism Spectrum Disorder/diagnosis Autistic Disorder/diagnosis Caregivers Child Cohort Studies Databases, Factual Female Humans Male Adults Autism Birth weight Electronic medical records Intellectual disability Language delay Parental report Regression SPARK cohort Sex differences Validity Index. décimale : PER Périodiques Résumé : The SPARK cohort was established to facilitate recruitment in studies of large numbers of participants with autism spectrum disorder (ASD). Online registration requires participants to have received a lifetime professional diagnosis by health or school providers although diagnoses are not independently verified. This study was set to examine the validity of self- and caregiver-reported autism diagnoses. Electronic medical records (EMR) of 254 SPARK participants (77.6% male, age 10.7Â years) were abstracted. Using two different methods, confirmation of ASD diagnosis in EMRs was obtained in 98.8% of cases. Core clinical features recorded in EMRs were typical of autism samples and showed very good agreement with SPARK cohort data, providing further evidence of the validity of clinical information in the SPARK database. En ligne : http://dx.doi.org/10.1007/s10803-021-05218-y Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=485